Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle

Anne Hamilton, Franco M. Muggia, Anne C. Pavlick et al.|Journal of Clinical Oncology|2005

Cited by 100